QUOTE AND NEWS
Benzinga  Jul 11  Comment 
Analysts at JP Morgan initiated coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Outperform rating. The target price for Halozyme Therapeutics is set to $13. Halozyme Therapeutics shares have gained 10.07% over the past 52 weeks,...
StreetInsider.com  Jun 25  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Halozyme+Therapeutics+%28HALO%29+Reports+Milestone+Triggered+with+MabThera+SC+Launch+in+Europe/9611816.html for the full story.
Motley Fool  Jun 12  Comment 
Halozyme shares shoot higher after receiving positive commentary from a Wall Street firm.
TheStreet.com  Jun 12  Comment 
NEW YORK (TheStreet) -- RATINGS CHANGES Halozyme Therapeutics was upgraded at UBS to buy from neutral, UBS said. Driven on pipeline potential and undervalued valuation, UBS said. Twelve-month price target is $16. Hewlett-Packard was upgraded...
TheStreet.com  Jun 12  Comment 
NEW YORK (TheStreet) -- Halozyme Therapeutics Inc.  was upgraded to "buy" from "neutral" at UBS this morning with an increased price target of $16 from $14. Said UBS: "We like the positioning from here. Upgrading...on pipeline potential and...
Benzinga  Jun 5  Comment 
Shares of Halozyme Therapeutics (NASDAQ: HALO) at one point spiked more than 20 percent following the U.S. Food and Drug Administration (FDA) removal of the clinical hold on PEGPH20. A Revised Protocol for PEGPH20 In a press release on...
TheStreet.com  Jun 5  Comment 
NEW YORK (TheStreet) -- Halozyme Therapeutics shares are rocketing up 14.1% to $9.22 following the announcement that the FDA lifted a hold on the clinical study of its pancreatic cancer treatment.The FDA ruled that the mid-stage study of the...
FierceBiotech  Jun 5  Comment 
Halozyme is back on track with a midstage trial of its in-development pancreatic cancer treatment after the FDA lifted its clinical hold on enrollment, news that sent the company's shares up as much as 20%.
Benzinga  Jun 5  Comment 
Halozyme Therapeutics (NASDAQ: HALO) climbed 17.57% to $9.50 after the company reported that it will resume PEGPH20 clinical program in pancreatic cancer. Ciena (NYSE: CIEN) shares gained 16.90% to $22.20 after the company reported upbeat...
StreetInsider.com  Jun 5  Comment 
NewLead Holdings Ltd. (Nasdaq: NEWL) 62.9% HIGHER; announced that on June 3, 2014, the Company was granted a Temporary Restraining Order, against Ironridge Global IV, Ltd. ("Ironridge") prohibiting the further issuance of common shares in...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki